Based on the key measurements obtained from Innate Pharma's financial statements, Innate Pharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At present, Innate Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Short and Long Term Debt Total is expected to grow to about 41.9 M, whereas Other Current Liabilities is forecasted to decline to about 14.8 M. Key indicators impacting Innate Pharma's financial strength include:
The financial analysis of Innate Pharma is a critical element in measuring its lifeblood. Investors should not minimize Innate Pharma's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(7.95 Million)
Innate
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Account Receivables
Change To Inventory
Investments
Net Borrowings
Total Cashflows From Investing Activities
Change To Operating Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Short Term Debt
Common Stock
Net Receivables
Accumulated Other Comprehensive Income
Other Assets
Inventory
Intangible Assets
Other Liab
Net Tangible Assets
Long Term Debt
Good Will
Capital Lease Obligations
Long Term Investments
Short Long Term Debt
Non Current Liabilities Other
Property Plant Equipment
Net Invested Capital
Net Working Capital
Capital Stock
Depreciation And Amortization
Interest Expense
Selling General Administrative
Selling And Marketing Expenses
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Discontinued Operations
Net Income From Continuing Ops
Research Development
Net Income Applicable To Common Shares
Net Interest Income
Reconciled Depreciation
Interest Income
Probability Of Bankruptcy
Understanding current and past Innate Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Innate Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Innate Pharma's assets may result in an increase in income on the income statement.
Please note, the presentation of Innate Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Innate Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Innate Pharma's management manipulating its earnings.
Innate Pharma Stock Summary
Innate Pharma competes with Eliem Therapeutics, HCW Biologics, Inhibrx, Anebulo Pharmaceuticals, and Shattuck Labs. Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company was incorporated in 1999 and is headquartered in Marseille, France. Innate Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 213 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Innate Pharma's current stock value. Our valuation model uses many indicators to compare Innate Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Innate Pharma competition to find correlations between indicators driving Innate Pharma's intrinsic value. More Info.
Innate Pharma is rated below average in return on equity category among its peers. It is rated third overall in return on asset category among its peers . At present, Innate Pharma's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Innate Pharma's earnings, one of the primary drivers of an investment's value.
Innate Pharma Systematic Risk
Innate Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Innate Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Innate Pharma correlated with the market. If Beta is less than 0 Innate Pharma generally moves in the opposite direction as compared to the market. If Innate Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Innate Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Innate Pharma is generally in the same direction as the market. If Beta > 1 Innate Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Innate Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Innate Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Innate Pharma growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.3
At present, Innate Pharma's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
Innate Pharma December 11, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Innate Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Innate Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Innate Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Innate Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Innate Pharma's daily price indicators and compare them against related drivers.
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance